nodes	percent_of_prediction	percent_of_DWPC	metapath
Darifenacin—CYP2D6—Efavirenz—acquired immunodeficiency syndrome	0.0562	0.0809	CbGbCtD
Darifenacin—CYP2D6—Nevirapine—acquired immunodeficiency syndrome	0.0529	0.0761	CbGbCtD
Darifenacin—CYP2D6—Lopinavir—acquired immunodeficiency syndrome	0.0529	0.0761	CbGbCtD
Darifenacin—CYP2D6—Delavirdine—acquired immunodeficiency syndrome	0.0478	0.0688	CbGbCtD
Darifenacin—CYP2D6—Amprenavir—acquired immunodeficiency syndrome	0.0478	0.0688	CbGbCtD
Darifenacin—CYP2D6—Indinavir—acquired immunodeficiency syndrome	0.0413	0.0594	CbGbCtD
Darifenacin—CYP2D6—Nelfinavir—acquired immunodeficiency syndrome	0.0401	0.0577	CbGbCtD
Darifenacin—CYP2D6—Saquinavir—acquired immunodeficiency syndrome	0.0362	0.0521	CbGbCtD
Darifenacin—CYP2D6—Ritonavir—acquired immunodeficiency syndrome	0.0362	0.0521	CbGbCtD
Darifenacin—CYP3A4—Efavirenz—acquired immunodeficiency syndrome	0.0358	0.0515	CbGbCtD
Darifenacin—CYP3A4—Lopinavir—acquired immunodeficiency syndrome	0.0336	0.0484	CbGbCtD
Darifenacin—CYP3A4—Nevirapine—acquired immunodeficiency syndrome	0.0336	0.0484	CbGbCtD
Darifenacin—CYP3A4—Amprenavir—acquired immunodeficiency syndrome	0.0304	0.0437	CbGbCtD
Darifenacin—CYP3A4—Delavirdine—acquired immunodeficiency syndrome	0.0304	0.0437	CbGbCtD
Darifenacin—CYP3A4—Indinavir—acquired immunodeficiency syndrome	0.0262	0.0378	CbGbCtD
Darifenacin—CYP3A4—Nelfinavir—acquired immunodeficiency syndrome	0.0255	0.0367	CbGbCtD
Darifenacin—CYP3A4—Saquinavir—acquired immunodeficiency syndrome	0.023	0.0332	CbGbCtD
Darifenacin—CYP3A4—Ritonavir—acquired immunodeficiency syndrome	0.023	0.0332	CbGbCtD
Darifenacin—CYP3A4—Zidovudine—acquired immunodeficiency syndrome	0.0221	0.0318	CbGbCtD
Darifenacin—CHRM5—skin of body—acquired immunodeficiency syndrome	0.000809	0.0836	CbGeAlD
Darifenacin—CHRM4—nervous system—acquired immunodeficiency syndrome	0.000641	0.0661	CbGeAlD
Darifenacin—CHRM4—central nervous system—acquired immunodeficiency syndrome	0.000617	0.0637	CbGeAlD
Darifenacin—CYP3A4—blood plasma—acquired immunodeficiency syndrome	0.000517	0.0534	CbGeAlD
Darifenacin—CYP2D6—blood plasma—acquired immunodeficiency syndrome	0.000509	0.0526	CbGeAlD
Darifenacin—CHRM5—nervous system—acquired immunodeficiency syndrome	0.000501	0.0517	CbGeAlD
Darifenacin—CHRM4—brain—acquired immunodeficiency syndrome	0.00049	0.0506	CbGeAlD
Darifenacin—CHRM5—central nervous system—acquired immunodeficiency syndrome	0.000482	0.0498	CbGeAlD
Darifenacin—CHRM5—brain—acquired immunodeficiency syndrome	0.000383	0.0395	CbGeAlD
Darifenacin—Back pain—Saquinavir—acquired immunodeficiency syndrome	0.000378	0.00133	CcSEcCtD
Darifenacin—Confusional state—Efavirenz—acquired immunodeficiency syndrome	0.000377	0.00133	CcSEcCtD
Darifenacin—Dyspepsia—Zidovudine—acquired immunodeficiency syndrome	0.000375	0.00132	CcSEcCtD
Darifenacin—Hypersensitivity—Nevirapine—acquired immunodeficiency syndrome	0.000374	0.00132	CcSEcCtD
Darifenacin—Arthralgia—Delavirdine—acquired immunodeficiency syndrome	0.000373	0.00131	CcSEcCtD
Darifenacin—Shock—Efavirenz—acquired immunodeficiency syndrome	0.000368	0.0013	CcSEcCtD
Darifenacin—Nausea—Amprenavir—acquired immunodeficiency syndrome	0.000368	0.00129	CcSEcCtD
Darifenacin—Gastrointestinal disorder—Zidovudine—acquired immunodeficiency syndrome	0.000368	0.00129	CcSEcCtD
Darifenacin—Flatulence—Lamivudine—acquired immunodeficiency syndrome	0.000367	0.00129	CcSEcCtD
Darifenacin—Nervous system disorder—Efavirenz—acquired immunodeficiency syndrome	0.000367	0.00129	CcSEcCtD
Darifenacin—Dry mouth—Delavirdine—acquired immunodeficiency syndrome	0.000365	0.00129	CcSEcCtD
Darifenacin—Tachycardia—Efavirenz—acquired immunodeficiency syndrome	0.000365	0.00129	CcSEcCtD
Darifenacin—Dysgeusia—Lamivudine—acquired immunodeficiency syndrome	0.000365	0.00128	CcSEcCtD
Darifenacin—Pain—Zidovudine—acquired immunodeficiency syndrome	0.000364	0.00128	CcSEcCtD
Darifenacin—Constipation—Zidovudine—acquired immunodeficiency syndrome	0.000364	0.00128	CcSEcCtD
Darifenacin—Asthenia—Nevirapine—acquired immunodeficiency syndrome	0.000364	0.00128	CcSEcCtD
Darifenacin—Syncope—Ritonavir—acquired immunodeficiency syndrome	0.000364	0.00128	CcSEcCtD
Darifenacin—Skin disorder—Efavirenz—acquired immunodeficiency syndrome	0.000363	0.00128	CcSEcCtD
Darifenacin—Hypersensitivity—Nelfinavir—acquired immunodeficiency syndrome	0.000362	0.00127	CcSEcCtD
Darifenacin—CHRM3—digestive system—acquired immunodeficiency syndrome	0.000362	0.0374	CbGeAlD
Darifenacin—Hyperhidrosis—Efavirenz—acquired immunodeficiency syndrome	0.000362	0.00127	CcSEcCtD
Darifenacin—Confusional state—Delavirdine—acquired immunodeficiency syndrome	0.000361	0.00127	CcSEcCtD
Darifenacin—Hypersensitivity—Stavudine—acquired immunodeficiency syndrome	0.000361	0.00127	CcSEcCtD
Darifenacin—Musculoskeletal discomfort—Indinavir—acquired immunodeficiency syndrome	0.000361	0.00127	CcSEcCtD
Darifenacin—Back pain—Lamivudine—acquired immunodeficiency syndrome	0.00036	0.00127	CcSEcCtD
Darifenacin—Pruritus—Nevirapine—acquired immunodeficiency syndrome	0.000359	0.00126	CcSEcCtD
Darifenacin—Vomiting—Didanosine—acquired immunodeficiency syndrome	0.000359	0.00126	CcSEcCtD
Darifenacin—Palpitations—Ritonavir—acquired immunodeficiency syndrome	0.000358	0.00126	CcSEcCtD
Darifenacin—Insomnia—Indinavir—acquired immunodeficiency syndrome	0.000358	0.00126	CcSEcCtD
Darifenacin—Oedema—Delavirdine—acquired immunodeficiency syndrome	0.000358	0.00126	CcSEcCtD
Darifenacin—Loss of consciousness—Ritonavir—acquired immunodeficiency syndrome	0.000357	0.00126	CcSEcCtD
Darifenacin—Rash—Didanosine—acquired immunodeficiency syndrome	0.000356	0.00125	CcSEcCtD
Darifenacin—Infection—Delavirdine—acquired immunodeficiency syndrome	0.000356	0.00125	CcSEcCtD
Darifenacin—Hypersensitivity—Abacavir—acquired immunodeficiency syndrome	0.000356	0.00125	CcSEcCtD
Darifenacin—Dermatitis—Didanosine—acquired immunodeficiency syndrome	0.000355	0.00125	CcSEcCtD
Darifenacin—Cough—Ritonavir—acquired immunodeficiency syndrome	0.000354	0.00125	CcSEcCtD
Darifenacin—Headache—Didanosine—acquired immunodeficiency syndrome	0.000354	0.00124	CcSEcCtD
Darifenacin—Dyspnoea—Indinavir—acquired immunodeficiency syndrome	0.000353	0.00124	CcSEcCtD
Darifenacin—Asthenia—Nelfinavir—acquired immunodeficiency syndrome	0.000353	0.00124	CcSEcCtD
Darifenacin—Shock—Delavirdine—acquired immunodeficiency syndrome	0.000352	0.00124	CcSEcCtD
Darifenacin—Somnolence—Indinavir—acquired immunodeficiency syndrome	0.000352	0.00124	CcSEcCtD
Darifenacin—Asthenia—Stavudine—acquired immunodeficiency syndrome	0.000352	0.00124	CcSEcCtD
Darifenacin—Feeling abnormal—Zidovudine—acquired immunodeficiency syndrome	0.000351	0.00124	CcSEcCtD
Darifenacin—Hypertension—Ritonavir—acquired immunodeficiency syndrome	0.00035	0.00123	CcSEcCtD
Darifenacin—Syncope—Saquinavir—acquired immunodeficiency syndrome	0.00035	0.00123	CcSEcCtD
Darifenacin—Tachycardia—Delavirdine—acquired immunodeficiency syndrome	0.000349	0.00123	CcSEcCtD
Darifenacin—Dyspepsia—Indinavir—acquired immunodeficiency syndrome	0.000349	0.00123	CcSEcCtD
Darifenacin—Gastrointestinal pain—Zidovudine—acquired immunodeficiency syndrome	0.000348	0.00123	CcSEcCtD
Darifenacin—Skin disorder—Delavirdine—acquired immunodeficiency syndrome	0.000348	0.00122	CcSEcCtD
Darifenacin—Pruritus—Nelfinavir—acquired immunodeficiency syndrome	0.000348	0.00122	CcSEcCtD
Darifenacin—Diarrhoea—Nevirapine—acquired immunodeficiency syndrome	0.000347	0.00122	CcSEcCtD
Darifenacin—Pruritus—Stavudine—acquired immunodeficiency syndrome	0.000347	0.00122	CcSEcCtD
Darifenacin—Asthenia—Abacavir—acquired immunodeficiency syndrome	0.000346	0.00122	CcSEcCtD
Darifenacin—Hyperhidrosis—Delavirdine—acquired immunodeficiency syndrome	0.000346	0.00122	CcSEcCtD
Darifenacin—Arthralgia—Ritonavir—acquired immunodeficiency syndrome	0.000345	0.00122	CcSEcCtD
Darifenacin—CHRM2—nervous system—acquired immunodeficiency syndrome	0.000344	0.0355	CbGeAlD
Darifenacin—Loss of consciousness—Saquinavir—acquired immunodeficiency syndrome	0.000343	0.00121	CcSEcCtD
Darifenacin—Unspecified disorder of skin and subcutaneous tissue—Ritonavir—acquired immunodeficiency syndrome	0.000343	0.00121	CcSEcCtD
Darifenacin—Gastrointestinal disorder—Indinavir—acquired immunodeficiency syndrome	0.000342	0.0012	CcSEcCtD
Darifenacin—Pruritus—Abacavir—acquired immunodeficiency syndrome	0.000341	0.0012	CcSEcCtD
Darifenacin—Musculoskeletal discomfort—Efavirenz—acquired immunodeficiency syndrome	0.000341	0.0012	CcSEcCtD
Darifenacin—Cough—Saquinavir—acquired immunodeficiency syndrome	0.000341	0.0012	CcSEcCtD
Darifenacin—Angioedema—Lamivudine—acquired immunodeficiency syndrome	0.00034	0.0012	CcSEcCtD
Darifenacin—Constipation—Indinavir—acquired immunodeficiency syndrome	0.000339	0.00119	CcSEcCtD
Darifenacin—Pain—Indinavir—acquired immunodeficiency syndrome	0.000339	0.00119	CcSEcCtD
Darifenacin—Insomnia—Efavirenz—acquired immunodeficiency syndrome	0.000338	0.00119	CcSEcCtD
Darifenacin—CHRM1—lung—acquired immunodeficiency syndrome	0.000338	0.0349	CbGeAlD
Darifenacin—Dry mouth—Ritonavir—acquired immunodeficiency syndrome	0.000338	0.00119	CcSEcCtD
Darifenacin—Hypertension—Saquinavir—acquired immunodeficiency syndrome	0.000337	0.00119	CcSEcCtD
Darifenacin—Abdominal pain—Zidovudine—acquired immunodeficiency syndrome	0.000337	0.00119	CcSEcCtD
Darifenacin—Diarrhoea—Nelfinavir—acquired immunodeficiency syndrome	0.000336	0.00118	CcSEcCtD
Darifenacin—Diarrhoea—Stavudine—acquired immunodeficiency syndrome	0.000335	0.00118	CcSEcCtD
Darifenacin—Nausea—Didanosine—acquired immunodeficiency syndrome	0.000335	0.00118	CcSEcCtD
Darifenacin—Syncope—Lamivudine—acquired immunodeficiency syndrome	0.000334	0.00118	CcSEcCtD
Darifenacin—Confusional state—Ritonavir—acquired immunodeficiency syndrome	0.000334	0.00118	CcSEcCtD
Darifenacin—Dyspnoea—Efavirenz—acquired immunodeficiency syndrome	0.000334	0.00117	CcSEcCtD
Darifenacin—Somnolence—Efavirenz—acquired immunodeficiency syndrome	0.000333	0.00117	CcSEcCtD
Darifenacin—Arthralgia—Saquinavir—acquired immunodeficiency syndrome	0.000332	0.00117	CcSEcCtD
Darifenacin—Oedema—Ritonavir—acquired immunodeficiency syndrome	0.000331	0.00117	CcSEcCtD
Darifenacin—CHRM2—central nervous system—acquired immunodeficiency syndrome	0.000331	0.0342	CbGeAlD
Darifenacin—Diarrhoea—Abacavir—acquired immunodeficiency syndrome	0.00033	0.00116	CcSEcCtD
Darifenacin—Unspecified disorder of skin and subcutaneous tissue—Saquinavir—acquired immunodeficiency syndrome	0.00033	0.00116	CcSEcCtD
Darifenacin—Dyspepsia—Efavirenz—acquired immunodeficiency syndrome	0.000329	0.00116	CcSEcCtD
Darifenacin—Loss of consciousness—Lamivudine—acquired immunodeficiency syndrome	0.000327	0.00115	CcSEcCtD
Darifenacin—Feeling abnormal—Indinavir—acquired immunodeficiency syndrome	0.000326	0.00115	CcSEcCtD
Darifenacin—Musculoskeletal discomfort—Delavirdine—acquired immunodeficiency syndrome	0.000326	0.00115	CcSEcCtD
Darifenacin—Shock—Ritonavir—acquired immunodeficiency syndrome	0.000326	0.00115	CcSEcCtD
Darifenacin—Dry mouth—Saquinavir—acquired immunodeficiency syndrome	0.000325	0.00114	CcSEcCtD
Darifenacin—Cough—Lamivudine—acquired immunodeficiency syndrome	0.000325	0.00114	CcSEcCtD
Darifenacin—Dizziness—Nelfinavir—acquired immunodeficiency syndrome	0.000325	0.00114	CcSEcCtD
Darifenacin—Nervous system disorder—Ritonavir—acquired immunodeficiency syndrome	0.000325	0.00114	CcSEcCtD
Darifenacin—Dizziness—Stavudine—acquired immunodeficiency syndrome	0.000324	0.00114	CcSEcCtD
Darifenacin—Gastrointestinal pain—Indinavir—acquired immunodeficiency syndrome	0.000324	0.00114	CcSEcCtD
Darifenacin—Insomnia—Delavirdine—acquired immunodeficiency syndrome	0.000324	0.00114	CcSEcCtD
Darifenacin—Tachycardia—Ritonavir—acquired immunodeficiency syndrome	0.000323	0.00114	CcSEcCtD
Darifenacin—Gastrointestinal disorder—Efavirenz—acquired immunodeficiency syndrome	0.000323	0.00114	CcSEcCtD
Darifenacin—Vomiting—Nevirapine—acquired immunodeficiency syndrome	0.000323	0.00114	CcSEcCtD
Darifenacin—Skin disorder—Ritonavir—acquired immunodeficiency syndrome	0.000322	0.00113	CcSEcCtD
Darifenacin—Confusional state—Saquinavir—acquired immunodeficiency syndrome	0.000321	0.00113	CcSEcCtD
Darifenacin—Hyperhidrosis—Ritonavir—acquired immunodeficiency syndrome	0.00032	0.00113	CcSEcCtD
Darifenacin—Pain—Efavirenz—acquired immunodeficiency syndrome	0.00032	0.00113	CcSEcCtD
Darifenacin—Constipation—Efavirenz—acquired immunodeficiency syndrome	0.00032	0.00113	CcSEcCtD
Darifenacin—Rash—Nevirapine—acquired immunodeficiency syndrome	0.00032	0.00113	CcSEcCtD
Darifenacin—Dermatitis—Nevirapine—acquired immunodeficiency syndrome	0.00032	0.00113	CcSEcCtD
Darifenacin—Dyspnoea—Delavirdine—acquired immunodeficiency syndrome	0.000319	0.00112	CcSEcCtD
Darifenacin—Dizziness—Abacavir—acquired immunodeficiency syndrome	0.000319	0.00112	CcSEcCtD
Darifenacin—Oedema—Saquinavir—acquired immunodeficiency syndrome	0.000319	0.00112	CcSEcCtD
Darifenacin—Somnolence—Delavirdine—acquired immunodeficiency syndrome	0.000318	0.00112	CcSEcCtD
Darifenacin—Headache—Nevirapine—acquired immunodeficiency syndrome	0.000318	0.00112	CcSEcCtD
Darifenacin—Arthralgia—Lamivudine—acquired immunodeficiency syndrome	0.000317	0.00112	CcSEcCtD
Darifenacin—Infection—Saquinavir—acquired immunodeficiency syndrome	0.000317	0.00111	CcSEcCtD
Darifenacin—Dyspepsia—Delavirdine—acquired immunodeficiency syndrome	0.000315	0.00111	CcSEcCtD
Darifenacin—Unspecified disorder of skin and subcutaneous tissue—Lamivudine—acquired immunodeficiency syndrome	0.000315	0.00111	CcSEcCtD
Darifenacin—Shock—Saquinavir—acquired immunodeficiency syndrome	0.000314	0.0011	CcSEcCtD
Darifenacin—Abdominal pain—Indinavir—acquired immunodeficiency syndrome	0.000313	0.0011	CcSEcCtD
Darifenacin—CHRM1—nervous system—acquired immunodeficiency syndrome	0.000313	0.0323	CbGeAlD
Darifenacin—Nervous system disorder—Saquinavir—acquired immunodeficiency syndrome	0.000312	0.0011	CcSEcCtD
Darifenacin—Vomiting—Nelfinavir—acquired immunodeficiency syndrome	0.000312	0.0011	CcSEcCtD
Darifenacin—Vomiting—Stavudine—acquired immunodeficiency syndrome	0.000312	0.0011	CcSEcCtD
Darifenacin—Dry mouth—Lamivudine—acquired immunodeficiency syndrome	0.00031	0.00109	CcSEcCtD
Darifenacin—Rash—Nelfinavir—acquired immunodeficiency syndrome	0.00031	0.00109	CcSEcCtD
Darifenacin—Dermatitis—Nelfinavir—acquired immunodeficiency syndrome	0.00031	0.00109	CcSEcCtD
Darifenacin—Skin disorder—Saquinavir—acquired immunodeficiency syndrome	0.00031	0.00109	CcSEcCtD
Darifenacin—Gastrointestinal disorder—Delavirdine—acquired immunodeficiency syndrome	0.000309	0.00109	CcSEcCtD
Darifenacin—Rash—Stavudine—acquired immunodeficiency syndrome	0.000309	0.00109	CcSEcCtD
Darifenacin—Dermatitis—Stavudine—acquired immunodeficiency syndrome	0.000309	0.00109	CcSEcCtD
Darifenacin—Feeling abnormal—Efavirenz—acquired immunodeficiency syndrome	0.000308	0.00109	CcSEcCtD
Darifenacin—Hyperhidrosis—Saquinavir—acquired immunodeficiency syndrome	0.000308	0.00108	CcSEcCtD
Darifenacin—Headache—Nelfinavir—acquired immunodeficiency syndrome	0.000308	0.00108	CcSEcCtD
Darifenacin—Headache—Stavudine—acquired immunodeficiency syndrome	0.000307	0.00108	CcSEcCtD
Darifenacin—Vomiting—Abacavir—acquired immunodeficiency syndrome	0.000307	0.00108	CcSEcCtD
Darifenacin—Confusional state—Lamivudine—acquired immunodeficiency syndrome	0.000307	0.00108	CcSEcCtD
Darifenacin—Constipation—Delavirdine—acquired immunodeficiency syndrome	0.000306	0.00108	CcSEcCtD
Darifenacin—Pain—Delavirdine—acquired immunodeficiency syndrome	0.000306	0.00108	CcSEcCtD
Darifenacin—Gastrointestinal pain—Efavirenz—acquired immunodeficiency syndrome	0.000306	0.00108	CcSEcCtD
Darifenacin—Asthenia—Zidovudine—acquired immunodeficiency syndrome	0.000306	0.00108	CcSEcCtD
Darifenacin—Rash—Abacavir—acquired immunodeficiency syndrome	0.000304	0.00107	CcSEcCtD
Darifenacin—Dermatitis—Abacavir—acquired immunodeficiency syndrome	0.000304	0.00107	CcSEcCtD
Darifenacin—Oedema—Lamivudine—acquired immunodeficiency syndrome	0.000304	0.00107	CcSEcCtD
Darifenacin—Anaphylactic shock—Lamivudine—acquired immunodeficiency syndrome	0.000304	0.00107	CcSEcCtD
Darifenacin—Headache—Abacavir—acquired immunodeficiency syndrome	0.000302	0.00106	CcSEcCtD
Darifenacin—Infection—Lamivudine—acquired immunodeficiency syndrome	0.000302	0.00106	CcSEcCtD
Darifenacin—Musculoskeletal discomfort—Ritonavir—acquired immunodeficiency syndrome	0.000302	0.00106	CcSEcCtD
Darifenacin—Nausea—Nevirapine—acquired immunodeficiency syndrome	0.000301	0.00106	CcSEcCtD
Darifenacin—Pruritus—Zidovudine—acquired immunodeficiency syndrome	0.000301	0.00106	CcSEcCtD
Darifenacin—CHRM1—central nervous system—acquired immunodeficiency syndrome	0.000301	0.0311	CbGeAlD
Darifenacin—Insomnia—Ritonavir—acquired immunodeficiency syndrome	0.000299	0.00105	CcSEcCtD
Darifenacin—Shock—Lamivudine—acquired immunodeficiency syndrome	0.000299	0.00105	CcSEcCtD
Darifenacin—Nervous system disorder—Lamivudine—acquired immunodeficiency syndrome	0.000298	0.00105	CcSEcCtD
Darifenacin—Abdominal pain—Efavirenz—acquired immunodeficiency syndrome	0.000296	0.00104	CcSEcCtD
Darifenacin—Skin disorder—Lamivudine—acquired immunodeficiency syndrome	0.000295	0.00104	CcSEcCtD
Darifenacin—Dyspnoea—Ritonavir—acquired immunodeficiency syndrome	0.000295	0.00104	CcSEcCtD
Darifenacin—Feeling abnormal—Delavirdine—acquired immunodeficiency syndrome	0.000295	0.00104	CcSEcCtD
Darifenacin—Somnolence—Ritonavir—acquired immunodeficiency syndrome	0.000294	0.00104	CcSEcCtD
Darifenacin—Hyperhidrosis—Lamivudine—acquired immunodeficiency syndrome	0.000294	0.00103	CcSEcCtD
Darifenacin—Gastrointestinal pain—Delavirdine—acquired immunodeficiency syndrome	0.000293	0.00103	CcSEcCtD
Darifenacin—Nausea—Nelfinavir—acquired immunodeficiency syndrome	0.000292	0.00103	CcSEcCtD
Darifenacin—Hypersensitivity—Indinavir—acquired immunodeficiency syndrome	0.000292	0.00103	CcSEcCtD
Darifenacin—Dyspepsia—Ritonavir—acquired immunodeficiency syndrome	0.000291	0.00103	CcSEcCtD
Darifenacin—Diarrhoea—Zidovudine—acquired immunodeficiency syndrome	0.000291	0.00103	CcSEcCtD
Darifenacin—Nausea—Stavudine—acquired immunodeficiency syndrome	0.000291	0.00102	CcSEcCtD
Darifenacin—Musculoskeletal discomfort—Saquinavir—acquired immunodeficiency syndrome	0.00029	0.00102	CcSEcCtD
Darifenacin—Insomnia—Saquinavir—acquired immunodeficiency syndrome	0.000288	0.00101	CcSEcCtD
Darifenacin—Nausea—Abacavir—acquired immunodeficiency syndrome	0.000287	0.00101	CcSEcCtD
Darifenacin—Gastrointestinal disorder—Ritonavir—acquired immunodeficiency syndrome	0.000286	0.00101	CcSEcCtD
Darifenacin—Asthenia—Indinavir—acquired immunodeficiency syndrome	0.000284	0.001	CcSEcCtD
Darifenacin—Dyspnoea—Saquinavir—acquired immunodeficiency syndrome	0.000284	0.001	CcSEcCtD
Darifenacin—Somnolence—Saquinavir—acquired immunodeficiency syndrome	0.000283	0.000997	CcSEcCtD
Darifenacin—Constipation—Ritonavir—acquired immunodeficiency syndrome	0.000283	0.000997	CcSEcCtD
Darifenacin—Pain—Ritonavir—acquired immunodeficiency syndrome	0.000283	0.000997	CcSEcCtD
Darifenacin—Abdominal pain—Delavirdine—acquired immunodeficiency syndrome	0.000283	0.000996	CcSEcCtD
Darifenacin—Dizziness—Zidovudine—acquired immunodeficiency syndrome	0.000282	0.000991	CcSEcCtD
Darifenacin—Dyspepsia—Saquinavir—acquired immunodeficiency syndrome	0.00028	0.000988	CcSEcCtD
Darifenacin—Pruritus—Indinavir—acquired immunodeficiency syndrome	0.00028	0.000986	CcSEcCtD
Darifenacin—CHRM3—nervous system—acquired immunodeficiency syndrome	0.00028	0.0289	CbGeAlD
Darifenacin—Musculoskeletal discomfort—Lamivudine—acquired immunodeficiency syndrome	0.000277	0.000975	CcSEcCtD
Darifenacin—Hypersensitivity—Efavirenz—acquired immunodeficiency syndrome	0.000276	0.000971	CcSEcCtD
Darifenacin—Gastrointestinal disorder—Saquinavir—acquired immunodeficiency syndrome	0.000275	0.000969	CcSEcCtD
Darifenacin—Insomnia—Lamivudine—acquired immunodeficiency syndrome	0.000275	0.000968	CcSEcCtD
Darifenacin—Feeling abnormal—Ritonavir—acquired immunodeficiency syndrome	0.000273	0.000961	CcSEcCtD
Darifenacin—Pain—Saquinavir—acquired immunodeficiency syndrome	0.000272	0.000959	CcSEcCtD
Darifenacin—Constipation—Saquinavir—acquired immunodeficiency syndrome	0.000272	0.000959	CcSEcCtD
Darifenacin—Dyspnoea—Lamivudine—acquired immunodeficiency syndrome	0.000271	0.000954	CcSEcCtD
Darifenacin—Diarrhoea—Indinavir—acquired immunodeficiency syndrome	0.000271	0.000954	CcSEcCtD
Darifenacin—Vomiting—Zidovudine—acquired immunodeficiency syndrome	0.000271	0.000953	CcSEcCtD
Darifenacin—Gastrointestinal pain—Ritonavir—acquired immunodeficiency syndrome	0.000271	0.000953	CcSEcCtD
Darifenacin—Somnolence—Lamivudine—acquired immunodeficiency syndrome	0.00027	0.000951	CcSEcCtD
Darifenacin—CHRM3—central nervous system—acquired immunodeficiency syndrome	0.00027	0.0278	CbGeAlD
Darifenacin—Rash—Zidovudine—acquired immunodeficiency syndrome	0.000268	0.000945	CcSEcCtD
Darifenacin—Asthenia—Efavirenz—acquired immunodeficiency syndrome	0.000268	0.000945	CcSEcCtD
Darifenacin—Dermatitis—Zidovudine—acquired immunodeficiency syndrome	0.000268	0.000944	CcSEcCtD
Darifenacin—Dyspepsia—Lamivudine—acquired immunodeficiency syndrome	0.000268	0.000942	CcSEcCtD
Darifenacin—Headache—Zidovudine—acquired immunodeficiency syndrome	0.000267	0.000939	CcSEcCtD
Darifenacin—Pruritus—Efavirenz—acquired immunodeficiency syndrome	0.000265	0.000932	CcSEcCtD
Darifenacin—Hypersensitivity—Delavirdine—acquired immunodeficiency syndrome	0.000264	0.000929	CcSEcCtD
Darifenacin—CHRM2—brain—acquired immunodeficiency syndrome	0.000263	0.0271	CbGeAlD
Darifenacin—Feeling abnormal—Saquinavir—acquired immunodeficiency syndrome	0.000263	0.000925	CcSEcCtD
Darifenacin—Gastrointestinal disorder—Lamivudine—acquired immunodeficiency syndrome	0.000262	0.000924	CcSEcCtD
Darifenacin—Dizziness—Indinavir—acquired immunodeficiency syndrome	0.000262	0.000922	CcSEcCtD
Darifenacin—Abdominal pain—Ritonavir—acquired immunodeficiency syndrome	0.000262	0.000921	CcSEcCtD
Darifenacin—Gastrointestinal pain—Saquinavir—acquired immunodeficiency syndrome	0.000261	0.000917	CcSEcCtD
Darifenacin—Pain—Lamivudine—acquired immunodeficiency syndrome	0.00026	0.000915	CcSEcCtD
Darifenacin—Constipation—Lamivudine—acquired immunodeficiency syndrome	0.00026	0.000915	CcSEcCtD
Darifenacin—Asthenia—Delavirdine—acquired immunodeficiency syndrome	0.000257	0.000904	CcSEcCtD
Darifenacin—Diarrhoea—Efavirenz—acquired immunodeficiency syndrome	0.000256	0.000901	CcSEcCtD
Darifenacin—Pruritus—Delavirdine—acquired immunodeficiency syndrome	0.000253	0.000892	CcSEcCtD
Darifenacin—Nausea—Zidovudine—acquired immunodeficiency syndrome	0.000253	0.000891	CcSEcCtD
Darifenacin—Abdominal pain—Saquinavir—acquired immunodeficiency syndrome	0.000252	0.000887	CcSEcCtD
Darifenacin—Vomiting—Indinavir—acquired immunodeficiency syndrome	0.000252	0.000887	CcSEcCtD
Darifenacin—Feeling abnormal—Lamivudine—acquired immunodeficiency syndrome	0.000251	0.000882	CcSEcCtD
Darifenacin—Rash—Indinavir—acquired immunodeficiency syndrome	0.00025	0.000879	CcSEcCtD
Darifenacin—Dermatitis—Indinavir—acquired immunodeficiency syndrome	0.000249	0.000878	CcSEcCtD
Darifenacin—Gastrointestinal pain—Lamivudine—acquired immunodeficiency syndrome	0.000249	0.000875	CcSEcCtD
Darifenacin—Headache—Indinavir—acquired immunodeficiency syndrome	0.000248	0.000874	CcSEcCtD
Darifenacin—Dizziness—Efavirenz—acquired immunodeficiency syndrome	0.000247	0.000871	CcSEcCtD
Darifenacin—Diarrhoea—Delavirdine—acquired immunodeficiency syndrome	0.000245	0.000862	CcSEcCtD
Darifenacin—Hypersensitivity—Ritonavir—acquired immunodeficiency syndrome	0.000244	0.000859	CcSEcCtD
Darifenacin—Abdominal pain—Lamivudine—acquired immunodeficiency syndrome	0.00024	0.000846	CcSEcCtD
Darifenacin—CHRM1—brain—acquired immunodeficiency syndrome	0.000239	0.0247	CbGeAlD
Darifenacin—Vomiting—Efavirenz—acquired immunodeficiency syndrome	0.000238	0.000838	CcSEcCtD
Darifenacin—Asthenia—Ritonavir—acquired immunodeficiency syndrome	0.000238	0.000836	CcSEcCtD
Darifenacin—Dizziness—Delavirdine—acquired immunodeficiency syndrome	0.000237	0.000834	CcSEcCtD
Darifenacin—Rash—Efavirenz—acquired immunodeficiency syndrome	0.000236	0.000831	CcSEcCtD
Darifenacin—Dermatitis—Efavirenz—acquired immunodeficiency syndrome	0.000236	0.00083	CcSEcCtD
Darifenacin—Nausea—Indinavir—acquired immunodeficiency syndrome	0.000235	0.000828	CcSEcCtD
Darifenacin—Hypersensitivity—Saquinavir—acquired immunodeficiency syndrome	0.000235	0.000827	CcSEcCtD
Darifenacin—Headache—Efavirenz—acquired immunodeficiency syndrome	0.000234	0.000825	CcSEcCtD
Darifenacin—Pruritus—Ritonavir—acquired immunodeficiency syndrome	0.000234	0.000825	CcSEcCtD
Darifenacin—Asthenia—Saquinavir—acquired immunodeficiency syndrome	0.000229	0.000805	CcSEcCtD
Darifenacin—Vomiting—Delavirdine—acquired immunodeficiency syndrome	0.000228	0.000801	CcSEcCtD
Darifenacin—Diarrhoea—Ritonavir—acquired immunodeficiency syndrome	0.000227	0.000798	CcSEcCtD
Darifenacin—Rash—Delavirdine—acquired immunodeficiency syndrome	0.000226	0.000795	CcSEcCtD
Darifenacin—Dermatitis—Delavirdine—acquired immunodeficiency syndrome	0.000226	0.000794	CcSEcCtD
Darifenacin—Pruritus—Saquinavir—acquired immunodeficiency syndrome	0.000225	0.000794	CcSEcCtD
Darifenacin—Headache—Delavirdine—acquired immunodeficiency syndrome	0.000224	0.00079	CcSEcCtD
Darifenacin—Hypersensitivity—Lamivudine—acquired immunodeficiency syndrome	0.000224	0.000789	CcSEcCtD
Darifenacin—Nausea—Efavirenz—acquired immunodeficiency syndrome	0.000222	0.000783	CcSEcCtD
Darifenacin—Dizziness—Ritonavir—acquired immunodeficiency syndrome	0.000219	0.000771	CcSEcCtD
Darifenacin—Asthenia—Lamivudine—acquired immunodeficiency syndrome	0.000218	0.000768	CcSEcCtD
Darifenacin—Diarrhoea—Saquinavir—acquired immunodeficiency syndrome	0.000218	0.000768	CcSEcCtD
Darifenacin—Pruritus—Lamivudine—acquired immunodeficiency syndrome	0.000215	0.000757	CcSEcCtD
Darifenacin—CHRM3—brain—acquired immunodeficiency syndrome	0.000214	0.0221	CbGeAlD
Darifenacin—Nausea—Delavirdine—acquired immunodeficiency syndrome	0.000213	0.000749	CcSEcCtD
Darifenacin—Dizziness—Saquinavir—acquired immunodeficiency syndrome	0.000211	0.000742	CcSEcCtD
Darifenacin—Vomiting—Ritonavir—acquired immunodeficiency syndrome	0.00021	0.000741	CcSEcCtD
Darifenacin—Rash—Ritonavir—acquired immunodeficiency syndrome	0.000209	0.000735	CcSEcCtD
Darifenacin—Dermatitis—Ritonavir—acquired immunodeficiency syndrome	0.000209	0.000734	CcSEcCtD
Darifenacin—Diarrhoea—Lamivudine—acquired immunodeficiency syndrome	0.000208	0.000732	CcSEcCtD
Darifenacin—Headache—Ritonavir—acquired immunodeficiency syndrome	0.000207	0.00073	CcSEcCtD
Darifenacin—Vomiting—Saquinavir—acquired immunodeficiency syndrome	0.000203	0.000713	CcSEcCtD
Darifenacin—Dizziness—Lamivudine—acquired immunodeficiency syndrome	0.000201	0.000708	CcSEcCtD
Darifenacin—Rash—Saquinavir—acquired immunodeficiency syndrome	0.000201	0.000707	CcSEcCtD
Darifenacin—Dermatitis—Saquinavir—acquired immunodeficiency syndrome	0.000201	0.000707	CcSEcCtD
Darifenacin—Headache—Saquinavir—acquired immunodeficiency syndrome	0.0002	0.000703	CcSEcCtD
Darifenacin—CYP3A4—digestive system—acquired immunodeficiency syndrome	0.000199	0.0205	CbGeAlD
Darifenacin—Nausea—Ritonavir—acquired immunodeficiency syndrome	0.000197	0.000692	CcSEcCtD
Darifenacin—CYP2D6—digestive system—acquired immunodeficiency syndrome	0.000196	0.0202	CbGeAlD
Darifenacin—Vomiting—Lamivudine—acquired immunodeficiency syndrome	0.000193	0.00068	CcSEcCtD
Darifenacin—Rash—Lamivudine—acquired immunodeficiency syndrome	0.000192	0.000675	CcSEcCtD
Darifenacin—Dermatitis—Lamivudine—acquired immunodeficiency syndrome	0.000191	0.000674	CcSEcCtD
Darifenacin—Headache—Lamivudine—acquired immunodeficiency syndrome	0.00019	0.00067	CcSEcCtD
Darifenacin—CYP3A4—blood—acquired immunodeficiency syndrome	0.00019	0.0196	CbGeAlD
Darifenacin—Nausea—Saquinavir—acquired immunodeficiency syndrome	0.000189	0.000666	CcSEcCtD
Darifenacin—CYP2D6—blood—acquired immunodeficiency syndrome	0.000186	0.0193	CbGeAlD
Darifenacin—Nausea—Lamivudine—acquired immunodeficiency syndrome	0.000181	0.000636	CcSEcCtD
Darifenacin—CYP3A4—nervous system—acquired immunodeficiency syndrome	0.000154	0.0159	CbGeAlD
Darifenacin—CYP2D6—nervous system—acquired immunodeficiency syndrome	0.000151	0.0156	CbGeAlD
Darifenacin—CYP3A4—central nervous system—acquired immunodeficiency syndrome	0.000148	0.0153	CbGeAlD
Darifenacin—CYP2D6—central nervous system—acquired immunodeficiency syndrome	0.000146	0.015	CbGeAlD
Darifenacin—CYP2D6—brain—acquired immunodeficiency syndrome	0.000116	0.0119	CbGeAlD
Darifenacin—CHRM2—GPCR ligand binding—ACKR1—acquired immunodeficiency syndrome	5.95e-05	0.00523	CbGpPWpGaD
Darifenacin—CHRM5—Class A/1 (Rhodopsin-like receptors)—CXCR4—acquired immunodeficiency syndrome	5.9e-05	0.00519	CbGpPWpGaD
Darifenacin—CHRM5—Class A/1 (Rhodopsin-like receptors)—CXCL12—acquired immunodeficiency syndrome	5.9e-05	0.00519	CbGpPWpGaD
Darifenacin—CHRM4—G alpha (i) signalling events—CCL5—acquired immunodeficiency syndrome	5.9e-05	0.00519	CbGpPWpGaD
Darifenacin—CHRM4—GPCR ligand binding—CCL3—acquired immunodeficiency syndrome	5.52e-05	0.00486	CbGpPWpGaD
Darifenacin—CHRM2—G alpha (i) signalling events—CCR2—acquired immunodeficiency syndrome	5.49e-05	0.00483	CbGpPWpGaD
Darifenacin—CHRM1—GPCR ligand binding—CCL4—acquired immunodeficiency syndrome	5.45e-05	0.00479	CbGpPWpGaD
Darifenacin—CHRM3—GPCR ligand binding—CCL4—acquired immunodeficiency syndrome	5.43e-05	0.00478	CbGpPWpGaD
Darifenacin—CHRM2—SIDS Susceptibility Pathways—IL10—acquired immunodeficiency syndrome	5.43e-05	0.00477	CbGpPWpGaD
Darifenacin—CHRM2—GPCR ligand binding—CCL4—acquired immunodeficiency syndrome	5.38e-05	0.00473	CbGpPWpGaD
Darifenacin—CHRM4—G alpha (i) signalling events—CCR5—acquired immunodeficiency syndrome	5.31e-05	0.00467	CbGpPWpGaD
Darifenacin—CHRM5—GPCR ligand binding—CCL3—acquired immunodeficiency syndrome	5.29e-05	0.00465	CbGpPWpGaD
Darifenacin—CHRM2—G alpha (i) signalling events—CXCR4—acquired immunodeficiency syndrome	5.16e-05	0.00454	CbGpPWpGaD
Darifenacin—CHRM2—G alpha (i) signalling events—CXCL12—acquired immunodeficiency syndrome	5.16e-05	0.00454	CbGpPWpGaD
Darifenacin—CHRM1—GPCRs, Class A Rhodopsin-like—CCR2—acquired immunodeficiency syndrome	5.16e-05	0.00454	CbGpPWpGaD
Darifenacin—CHRM3—GPCRs, Class A Rhodopsin-like—CCR2—acquired immunodeficiency syndrome	5.14e-05	0.00452	CbGpPWpGaD
Darifenacin—CHRM1—Signaling by GPCR—CCL3L1—acquired immunodeficiency syndrome	5.1e-05	0.00449	CbGpPWpGaD
Darifenacin—CHRM2—GPCRs, Class A Rhodopsin-like—CCR2—acquired immunodeficiency syndrome	5.09e-05	0.00448	CbGpPWpGaD
Darifenacin—CHRM3—Signaling by GPCR—CCL3L1—acquired immunodeficiency syndrome	5.09e-05	0.00447	CbGpPWpGaD
Darifenacin—CHRM2—Signaling by GPCR—CCL3L1—acquired immunodeficiency syndrome	5.04e-05	0.00443	CbGpPWpGaD
Darifenacin—CHRM4—GPCR ligand binding—CCR2—acquired immunodeficiency syndrome	4.99e-05	0.00439	CbGpPWpGaD
Darifenacin—CHRM4—GPCRs, Class A Rhodopsin-like—CCR5—acquired immunodeficiency syndrome	4.93e-05	0.00434	CbGpPWpGaD
Darifenacin—CHRM1—Class A/1 (Rhodopsin-like receptors)—CCL3—acquired immunodeficiency syndrome	4.89e-05	0.0043	CbGpPWpGaD
Darifenacin—CHRM3—Class A/1 (Rhodopsin-like receptors)—CCL3—acquired immunodeficiency syndrome	4.87e-05	0.00429	CbGpPWpGaD
Darifenacin—CHRM1—GPCRs, Class A Rhodopsin-like—CXCR4—acquired immunodeficiency syndrome	4.85e-05	0.00427	CbGpPWpGaD
Darifenacin—CHRM3—GPCRs, Class A Rhodopsin-like—CXCR4—acquired immunodeficiency syndrome	4.84e-05	0.00425	CbGpPWpGaD
Darifenacin—CHRM2—Class A/1 (Rhodopsin-like receptors)—CCL3—acquired immunodeficiency syndrome	4.83e-05	0.00424	CbGpPWpGaD
Darifenacin—CHRM2—GPCRs, Class A Rhodopsin-like—CXCR4—acquired immunodeficiency syndrome	4.79e-05	0.00421	CbGpPWpGaD
Darifenacin—CHRM5—GPCR ligand binding—CCR2—acquired immunodeficiency syndrome	4.78e-05	0.00421	CbGpPWpGaD
Darifenacin—CHRM5—GPCRs, Class A Rhodopsin-like—CCR5—acquired immunodeficiency syndrome	4.72e-05	0.00415	CbGpPWpGaD
Darifenacin—CHRM4—GPCR ligand binding—CXCR4—acquired immunodeficiency syndrome	4.69e-05	0.00413	CbGpPWpGaD
Darifenacin—CHRM4—GPCR ligand binding—CXCL12—acquired immunodeficiency syndrome	4.69e-05	0.00413	CbGpPWpGaD
Darifenacin—CHRM4—Class A/1 (Rhodopsin-like receptors)—CCL5—acquired immunodeficiency syndrome	4.69e-05	0.00412	CbGpPWpGaD
Darifenacin—CHRM4—Signaling by GPCR—ACKR1—acquired immunodeficiency syndrome	4.59e-05	0.00403	CbGpPWpGaD
Darifenacin—CHRM5—GPCR ligand binding—CXCL12—acquired immunodeficiency syndrome	4.5e-05	0.00395	CbGpPWpGaD
Darifenacin—CHRM5—GPCR ligand binding—CXCR4—acquired immunodeficiency syndrome	4.5e-05	0.00395	CbGpPWpGaD
Darifenacin—CHRM5—Class A/1 (Rhodopsin-like receptors)—CCL5—acquired immunodeficiency syndrome	4.49e-05	0.00395	CbGpPWpGaD
Darifenacin—CHRM4—Signaling Pathways—CCL3L1—acquired immunodeficiency syndrome	4.47e-05	0.00393	CbGpPWpGaD
Darifenacin—CHRM1—Class A/1 (Rhodopsin-like receptors)—CCR2—acquired immunodeficiency syndrome	4.42e-05	0.00389	CbGpPWpGaD
Darifenacin—CHRM3—Class A/1 (Rhodopsin-like receptors)—CCR2—acquired immunodeficiency syndrome	4.41e-05	0.00388	CbGpPWpGaD
Darifenacin—CHRM5—Signaling by GPCR—ACKR1—acquired immunodeficiency syndrome	4.39e-05	0.00386	CbGpPWpGaD
Darifenacin—CHRM2—Class A/1 (Rhodopsin-like receptors)—CCR2—acquired immunodeficiency syndrome	4.36e-05	0.00384	CbGpPWpGaD
Darifenacin—CHRM5—Signaling Pathways—CCL3L1—acquired immunodeficiency syndrome	4.28e-05	0.00377	CbGpPWpGaD
Darifenacin—CHRM4—Class A/1 (Rhodopsin-like receptors)—CCR5—acquired immunodeficiency syndrome	4.23e-05	0.00372	CbGpPWpGaD
Darifenacin—CHRM1—Class A/1 (Rhodopsin-like receptors)—CXCL12—acquired immunodeficiency syndrome	4.16e-05	0.00366	CbGpPWpGaD
Darifenacin—CHRM1—Class A/1 (Rhodopsin-like receptors)—CXCR4—acquired immunodeficiency syndrome	4.16e-05	0.00366	CbGpPWpGaD
Darifenacin—CHRM4—Signaling by GPCR—CCL4—acquired immunodeficiency syndrome	4.15e-05	0.00365	CbGpPWpGaD
Darifenacin—CHRM3—Class A/1 (Rhodopsin-like receptors)—CXCR4—acquired immunodeficiency syndrome	4.14e-05	0.00364	CbGpPWpGaD
Darifenacin—CHRM3—Class A/1 (Rhodopsin-like receptors)—CXCL12—acquired immunodeficiency syndrome	4.14e-05	0.00364	CbGpPWpGaD
Darifenacin—CHRM2—Class A/1 (Rhodopsin-like receptors)—CXCR4—acquired immunodeficiency syndrome	4.1e-05	0.00361	CbGpPWpGaD
Darifenacin—CHRM2—Class A/1 (Rhodopsin-like receptors)—CXCL12—acquired immunodeficiency syndrome	4.1e-05	0.00361	CbGpPWpGaD
Darifenacin—CHRM5—Class A/1 (Rhodopsin-like receptors)—CCR5—acquired immunodeficiency syndrome	4.05e-05	0.00356	CbGpPWpGaD
Darifenacin—CHRM5—Signaling by GPCR—CCL4—acquired immunodeficiency syndrome	3.97e-05	0.00349	CbGpPWpGaD
Darifenacin—CHRM2—G alpha (i) signalling events—CCL5—acquired immunodeficiency syndrome	3.93e-05	0.00345	CbGpPWpGaD
Darifenacin—CHRM1—GPCR ligand binding—CCL3—acquired immunodeficiency syndrome	3.72e-05	0.00327	CbGpPWpGaD
Darifenacin—CHRM3—GPCR ligand binding—CCL3—acquired immunodeficiency syndrome	3.71e-05	0.00326	CbGpPWpGaD
Darifenacin—CHRM2—GPCR ligand binding—CCL3—acquired immunodeficiency syndrome	3.67e-05	0.00323	CbGpPWpGaD
Darifenacin—CHRM4—GPCR ligand binding—CCL5—acquired immunodeficiency syndrome	3.57e-05	0.00314	CbGpPWpGaD
Darifenacin—CHRM2—G alpha (i) signalling events—CCR5—acquired immunodeficiency syndrome	3.54e-05	0.00311	CbGpPWpGaD
Darifenacin—CHRM5—GPCR ligand binding—CCL5—acquired immunodeficiency syndrome	3.42e-05	0.00301	CbGpPWpGaD
Darifenacin—CHRM1—GPCR ligand binding—CCR2—acquired immunodeficiency syndrome	3.37e-05	0.00296	CbGpPWpGaD
Darifenacin—CHRM3—GPCR ligand binding—CCR2—acquired immunodeficiency syndrome	3.36e-05	0.00295	CbGpPWpGaD
Darifenacin—CHRM1—GPCRs, Class A Rhodopsin-like—CCR5—acquired immunodeficiency syndrome	3.33e-05	0.00292	CbGpPWpGaD
Darifenacin—CHRM2—GPCR ligand binding—CCR2—acquired immunodeficiency syndrome	3.32e-05	0.00292	CbGpPWpGaD
Darifenacin—CHRM3—GPCRs, Class A Rhodopsin-like—CCR5—acquired immunodeficiency syndrome	3.31e-05	0.00292	CbGpPWpGaD
Darifenacin—CHRM2—GPCRs, Class A Rhodopsin-like—CCR5—acquired immunodeficiency syndrome	3.28e-05	0.00289	CbGpPWpGaD
Darifenacin—CHRM4—GPCR ligand binding—CCR5—acquired immunodeficiency syndrome	3.22e-05	0.00283	CbGpPWpGaD
Darifenacin—CHRM3—Metabolism—TAT—acquired immunodeficiency syndrome	3.2e-05	0.00282	CbGpPWpGaD
Darifenacin—CHRM1—GPCR ligand binding—CXCR4—acquired immunodeficiency syndrome	3.17e-05	0.00278	CbGpPWpGaD
Darifenacin—CHRM1—GPCR ligand binding—CXCL12—acquired immunodeficiency syndrome	3.17e-05	0.00278	CbGpPWpGaD
Darifenacin—CHRM1—Class A/1 (Rhodopsin-like receptors)—CCL5—acquired immunodeficiency syndrome	3.16e-05	0.00278	CbGpPWpGaD
Darifenacin—CHRM3—GPCR ligand binding—CXCL12—acquired immunodeficiency syndrome	3.16e-05	0.00277	CbGpPWpGaD
Darifenacin—CHRM3—GPCR ligand binding—CXCR4—acquired immunodeficiency syndrome	3.16e-05	0.00277	CbGpPWpGaD
Darifenacin—CHRM3—Class A/1 (Rhodopsin-like receptors)—CCL5—acquired immunodeficiency syndrome	3.15e-05	0.00277	CbGpPWpGaD
Darifenacin—CHRM2—GPCR ligand binding—CXCL12—acquired immunodeficiency syndrome	3.12e-05	0.00275	CbGpPWpGaD
Darifenacin—CHRM2—GPCR ligand binding—CXCR4—acquired immunodeficiency syndrome	3.12e-05	0.00275	CbGpPWpGaD
Darifenacin—CHRM2—Class A/1 (Rhodopsin-like receptors)—CCL5—acquired immunodeficiency syndrome	3.12e-05	0.00275	CbGpPWpGaD
Darifenacin—CHRM1—Signaling by GPCR—ACKR1—acquired immunodeficiency syndrome	3.09e-05	0.00272	CbGpPWpGaD
Darifenacin—CHRM3—Signaling by GPCR—ACKR1—acquired immunodeficiency syndrome	3.08e-05	0.00271	CbGpPWpGaD
Darifenacin—CHRM5—GPCR ligand binding—CCR5—acquired immunodeficiency syndrome	3.08e-05	0.00271	CbGpPWpGaD
Darifenacin—CHRM2—Signaling by GPCR—ACKR1—acquired immunodeficiency syndrome	3.05e-05	0.00268	CbGpPWpGaD
Darifenacin—CHRM1—Signaling Pathways—CCL3L1—acquired immunodeficiency syndrome	3.02e-05	0.00265	CbGpPWpGaD
Darifenacin—CHRM3—Signaling Pathways—CCL3L1—acquired immunodeficiency syndrome	3.01e-05	0.00264	CbGpPWpGaD
Darifenacin—CHRM2—Signaling Pathways—CCL3L1—acquired immunodeficiency syndrome	2.98e-05	0.00262	CbGpPWpGaD
Darifenacin—CHRM1—Class A/1 (Rhodopsin-like receptors)—CCR5—acquired immunodeficiency syndrome	2.85e-05	0.00251	CbGpPWpGaD
Darifenacin—CHRM3—Class A/1 (Rhodopsin-like receptors)—CCR5—acquired immunodeficiency syndrome	2.84e-05	0.0025	CbGpPWpGaD
Darifenacin—CHRM4—Signaling by GPCR—CCL3—acquired immunodeficiency syndrome	2.83e-05	0.00249	CbGpPWpGaD
Darifenacin—CHRM4—GPCR downstream signaling—CCR2—acquired immunodeficiency syndrome	2.82e-05	0.00248	CbGpPWpGaD
Darifenacin—CHRM2—Class A/1 (Rhodopsin-like receptors)—CCR5—acquired immunodeficiency syndrome	2.81e-05	0.00247	CbGpPWpGaD
Darifenacin—CHRM1—Signaling by GPCR—CCL4—acquired immunodeficiency syndrome	2.8e-05	0.00246	CbGpPWpGaD
Darifenacin—CHRM3—Signaling by GPCR—CCL4—acquired immunodeficiency syndrome	2.79e-05	0.00245	CbGpPWpGaD
Darifenacin—CHRM2—Signaling by GPCR—CCL4—acquired immunodeficiency syndrome	2.76e-05	0.00243	CbGpPWpGaD
Darifenacin—CHRM3—Metabolism—AGPS—acquired immunodeficiency syndrome	2.72e-05	0.0024	CbGpPWpGaD
Darifenacin—CHRM5—Signaling by GPCR—CCL3—acquired immunodeficiency syndrome	2.71e-05	0.00239	CbGpPWpGaD
Darifenacin—CHRM4—Signaling Pathways—ACKR1—acquired immunodeficiency syndrome	2.71e-05	0.00238	CbGpPWpGaD
Darifenacin—CHRM4—Signaling Pathways—CCNT1—acquired immunodeficiency syndrome	2.71e-05	0.00238	CbGpPWpGaD
Darifenacin—CHRM5—GPCR downstream signaling—CCR2—acquired immunodeficiency syndrome	2.7e-05	0.00238	CbGpPWpGaD
Darifenacin—CHRM4—GPCR downstream signaling—CXCR4—acquired immunodeficiency syndrome	2.65e-05	0.00233	CbGpPWpGaD
Darifenacin—CHRM4—GPCR downstream signaling—CXCL12—acquired immunodeficiency syndrome	2.65e-05	0.00233	CbGpPWpGaD
Darifenacin—CHRM5—Signaling Pathways—CCNT1—acquired immunodeficiency syndrome	2.59e-05	0.00228	CbGpPWpGaD
Darifenacin—CHRM5—Signaling Pathways—ACKR1—acquired immunodeficiency syndrome	2.59e-05	0.00228	CbGpPWpGaD
Darifenacin—CHRM4—Signaling by GPCR—CCR2—acquired immunodeficiency syndrome	2.56e-05	0.00225	CbGpPWpGaD
Darifenacin—CHRM5—GPCR downstream signaling—CXCL12—acquired immunodeficiency syndrome	2.54e-05	0.00223	CbGpPWpGaD
Darifenacin—CHRM5—GPCR downstream signaling—CXCR4—acquired immunodeficiency syndrome	2.54e-05	0.00223	CbGpPWpGaD
Darifenacin—CHRM5—Signaling by GPCR—CCR2—acquired immunodeficiency syndrome	2.45e-05	0.00216	CbGpPWpGaD
Darifenacin—CHRM4—Signaling Pathways—CCL4—acquired immunodeficiency syndrome	2.45e-05	0.00215	CbGpPWpGaD
Darifenacin—CHRM4—Signaling by GPCR—CXCL12—acquired immunodeficiency syndrome	2.41e-05	0.00212	CbGpPWpGaD
Darifenacin—CHRM4—Signaling by GPCR—CXCR4—acquired immunodeficiency syndrome	2.41e-05	0.00212	CbGpPWpGaD
Darifenacin—CHRM1—GPCR ligand binding—CCL5—acquired immunodeficiency syndrome	2.41e-05	0.00212	CbGpPWpGaD
Darifenacin—CHRM3—GPCR ligand binding—CCL5—acquired immunodeficiency syndrome	2.4e-05	0.00211	CbGpPWpGaD
Darifenacin—CHRM2—GPCR ligand binding—CCL5—acquired immunodeficiency syndrome	2.38e-05	0.00209	CbGpPWpGaD
Darifenacin—CHRM5—Signaling Pathways—CCL4—acquired immunodeficiency syndrome	2.35e-05	0.00206	CbGpPWpGaD
Darifenacin—CHRM5—Signaling by GPCR—CXCL12—acquired immunodeficiency syndrome	2.31e-05	0.00203	CbGpPWpGaD
Darifenacin—CHRM5—Signaling by GPCR—CXCR4—acquired immunodeficiency syndrome	2.31e-05	0.00203	CbGpPWpGaD
Darifenacin—CHRM1—GPCR ligand binding—CCR5—acquired immunodeficiency syndrome	2.17e-05	0.00191	CbGpPWpGaD
Darifenacin—CHRM3—GPCR ligand binding—CCR5—acquired immunodeficiency syndrome	2.16e-05	0.0019	CbGpPWpGaD
Darifenacin—CHRM2—GPCR ligand binding—CCR5—acquired immunodeficiency syndrome	2.14e-05	0.00188	CbGpPWpGaD
Darifenacin—CHRM2—SIDS Susceptibility Pathways—TNF—acquired immunodeficiency syndrome	2.07e-05	0.00182	CbGpPWpGaD
Darifenacin—CHRM4—GPCR downstream signaling—CCL5—acquired immunodeficiency syndrome	2.02e-05	0.00177	CbGpPWpGaD
Darifenacin—CHRM4—GPCR downstream signaling—CSF2—acquired immunodeficiency syndrome	1.99e-05	0.00175	CbGpPWpGaD
Darifenacin—CHRM5—GPCR downstream signaling—CCL5—acquired immunodeficiency syndrome	1.93e-05	0.0017	CbGpPWpGaD
Darifenacin—CYP2D6—Metabolism—TAT—acquired immunodeficiency syndrome	1.92e-05	0.00168	CbGpPWpGaD
Darifenacin—CHRM1—Signaling by GPCR—CCL3—acquired immunodeficiency syndrome	1.91e-05	0.00168	CbGpPWpGaD
Darifenacin—CHRM3—Signaling by GPCR—CCL3—acquired immunodeficiency syndrome	1.9e-05	0.00167	CbGpPWpGaD
Darifenacin—CHRM5—GPCR downstream signaling—CSF2—acquired immunodeficiency syndrome	1.9e-05	0.00167	CbGpPWpGaD
Darifenacin—CHRM1—GPCR downstream signaling—CCR2—acquired immunodeficiency syndrome	1.9e-05	0.00167	CbGpPWpGaD
Darifenacin—CHRM3—GPCR downstream signaling—CCR2—acquired immunodeficiency syndrome	1.9e-05	0.00167	CbGpPWpGaD
Darifenacin—CHRM2—Signaling by GPCR—CCL3—acquired immunodeficiency syndrome	1.89e-05	0.00166	CbGpPWpGaD
Darifenacin—CHRM2—GPCR downstream signaling—CCR2—acquired immunodeficiency syndrome	1.88e-05	0.00165	CbGpPWpGaD
Darifenacin—CHRM5—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—acquired immunodeficiency syndrome	1.86e-05	0.00163	CbGpPWpGaD
Darifenacin—CHRM4—Signaling by GPCR—CCL5—acquired immunodeficiency syndrome	1.83e-05	0.00161	CbGpPWpGaD
Darifenacin—CHRM1—Signaling Pathways—CCNT1—acquired immunodeficiency syndrome	1.83e-05	0.00161	CbGpPWpGaD
Darifenacin—CHRM1—Signaling Pathways—ACKR1—acquired immunodeficiency syndrome	1.83e-05	0.00161	CbGpPWpGaD
Darifenacin—CHRM3—Signaling Pathways—CCNT1—acquired immunodeficiency syndrome	1.82e-05	0.0016	CbGpPWpGaD
Darifenacin—CHRM3—Signaling Pathways—ACKR1—acquired immunodeficiency syndrome	1.82e-05	0.0016	CbGpPWpGaD
Darifenacin—CHRM4—GPCR downstream signaling—CCR5—acquired immunodeficiency syndrome	1.82e-05	0.0016	CbGpPWpGaD
Darifenacin—CHRM4—Signaling by GPCR—CSF2—acquired immunodeficiency syndrome	1.81e-05	0.00159	CbGpPWpGaD
Darifenacin—CHRM2—Signaling Pathways—CCNT1—acquired immunodeficiency syndrome	1.8e-05	0.00159	CbGpPWpGaD
Darifenacin—CHRM2—Signaling Pathways—ACKR1—acquired immunodeficiency syndrome	1.8e-05	0.00159	CbGpPWpGaD
Darifenacin—CHRM1—GPCR downstream signaling—CXCL12—acquired immunodeficiency syndrome	1.79e-05	0.00157	CbGpPWpGaD
Darifenacin—CHRM1—GPCR downstream signaling—CXCR4—acquired immunodeficiency syndrome	1.79e-05	0.00157	CbGpPWpGaD
Darifenacin—CHRM3—GPCR downstream signaling—CXCL12—acquired immunodeficiency syndrome	1.78e-05	0.00157	CbGpPWpGaD
Darifenacin—CHRM3—GPCR downstream signaling—CXCR4—acquired immunodeficiency syndrome	1.78e-05	0.00157	CbGpPWpGaD
Darifenacin—CHRM2—GPCR downstream signaling—CXCL12—acquired immunodeficiency syndrome	1.77e-05	0.00155	CbGpPWpGaD
Darifenacin—CHRM2—GPCR downstream signaling—CXCR4—acquired immunodeficiency syndrome	1.77e-05	0.00155	CbGpPWpGaD
Darifenacin—CHRM5—Signaling by GPCR—CCL5—acquired immunodeficiency syndrome	1.76e-05	0.00154	CbGpPWpGaD
Darifenacin—CHRM5—GPCR downstream signaling—CCR5—acquired immunodeficiency syndrome	1.74e-05	0.00153	CbGpPWpGaD
Darifenacin—CHRM5—Signaling by GPCR—CSF2—acquired immunodeficiency syndrome	1.73e-05	0.00152	CbGpPWpGaD
Darifenacin—CHRM1—Signaling by GPCR—CCR2—acquired immunodeficiency syndrome	1.73e-05	0.00152	CbGpPWpGaD
Darifenacin—CHRM3—Signaling by GPCR—CCR2—acquired immunodeficiency syndrome	1.72e-05	0.00151	CbGpPWpGaD
Darifenacin—CHRM2—Signaling by GPCR—CCR2—acquired immunodeficiency syndrome	1.71e-05	0.0015	CbGpPWpGaD
Darifenacin—CHRM4—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	1.67e-05	0.00147	CbGpPWpGaD
Darifenacin—CHRM2—SIDS Susceptibility Pathways—IL6—acquired immunodeficiency syndrome	1.67e-05	0.00147	CbGpPWpGaD
Darifenacin—CHRM1—Signaling Pathways—CCL4—acquired immunodeficiency syndrome	1.65e-05	0.00145	CbGpPWpGaD
Darifenacin—CHRM4—Signaling by GPCR—CCR5—acquired immunodeficiency syndrome	1.65e-05	0.00145	CbGpPWpGaD
Darifenacin—CHRM3—Signaling Pathways—CCL4—acquired immunodeficiency syndrome	1.65e-05	0.00145	CbGpPWpGaD
Darifenacin—CHRM2—Signaling Pathways—CCL4—acquired immunodeficiency syndrome	1.63e-05	0.00143	CbGpPWpGaD
Darifenacin—CYP2D6—Metabolism—AGPS—acquired immunodeficiency syndrome	1.63e-05	0.00143	CbGpPWpGaD
Darifenacin—CHRM1—Signaling by GPCR—CXCL12—acquired immunodeficiency syndrome	1.62e-05	0.00143	CbGpPWpGaD
Darifenacin—CHRM1—Signaling by GPCR—CXCR4—acquired immunodeficiency syndrome	1.62e-05	0.00143	CbGpPWpGaD
Darifenacin—CHRM3—Signaling by GPCR—CXCR4—acquired immunodeficiency syndrome	1.62e-05	0.00142	CbGpPWpGaD
Darifenacin—CHRM3—Signaling by GPCR—CXCL12—acquired immunodeficiency syndrome	1.62e-05	0.00142	CbGpPWpGaD
Darifenacin—CHRM2—Signaling by GPCR—CXCR4—acquired immunodeficiency syndrome	1.6e-05	0.00141	CbGpPWpGaD
Darifenacin—CHRM2—Signaling by GPCR—CXCL12—acquired immunodeficiency syndrome	1.6e-05	0.00141	CbGpPWpGaD
Darifenacin—CHRM5—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	1.6e-05	0.00141	CbGpPWpGaD
Darifenacin—CHRM5—Signaling by GPCR—CCR5—acquired immunodeficiency syndrome	1.58e-05	0.00139	CbGpPWpGaD
Darifenacin—CHRM4—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	1.51e-05	0.00133	CbGpPWpGaD
Darifenacin—CHRM5—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	1.45e-05	0.00127	CbGpPWpGaD
Darifenacin—CHRM4—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	1.42e-05	0.00125	CbGpPWpGaD
Darifenacin—CHRM4—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	1.42e-05	0.00125	CbGpPWpGaD
Darifenacin—CHRM1—Circadian rythm related genes—IL6—acquired immunodeficiency syndrome	1.38e-05	0.00121	CbGpPWpGaD
Darifenacin—CHRM5—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	1.36e-05	0.0012	CbGpPWpGaD
Darifenacin—CHRM5—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	1.36e-05	0.0012	CbGpPWpGaD
Darifenacin—CHRM1—GPCR downstream signaling—CCL5—acquired immunodeficiency syndrome	1.36e-05	0.0012	CbGpPWpGaD
Darifenacin—CHRM3—GPCR downstream signaling—CCL5—acquired immunodeficiency syndrome	1.36e-05	0.00119	CbGpPWpGaD
Darifenacin—CHRM2—GPCR downstream signaling—CCL5—acquired immunodeficiency syndrome	1.34e-05	0.00118	CbGpPWpGaD
Darifenacin—CHRM1—GPCR downstream signaling—CSF2—acquired immunodeficiency syndrome	1.34e-05	0.00118	CbGpPWpGaD
Darifenacin—CHRM3—GPCR downstream signaling—CSF2—acquired immunodeficiency syndrome	1.34e-05	0.00118	CbGpPWpGaD
Darifenacin—CHRM2—GPCR downstream signaling—CSF2—acquired immunodeficiency syndrome	1.32e-05	0.00116	CbGpPWpGaD
Darifenacin—CHRM1—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—acquired immunodeficiency syndrome	1.31e-05	0.00115	CbGpPWpGaD
Darifenacin—CHRM3—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—acquired immunodeficiency syndrome	1.3e-05	0.00115	CbGpPWpGaD
Darifenacin—CYP3A4—Metabolism—TAT—acquired immunodeficiency syndrome	1.25e-05	0.0011	CbGpPWpGaD
Darifenacin—CHRM1—Signaling by GPCR—CCL5—acquired immunodeficiency syndrome	1.24e-05	0.00109	CbGpPWpGaD
Darifenacin—CHRM3—Signaling by GPCR—CCL5—acquired immunodeficiency syndrome	1.23e-05	0.00108	CbGpPWpGaD
Darifenacin—CHRM1—GPCR downstream signaling—CCR5—acquired immunodeficiency syndrome	1.23e-05	0.00108	CbGpPWpGaD
Darifenacin—CHRM3—GPCR downstream signaling—CCR5—acquired immunodeficiency syndrome	1.22e-05	0.00107	CbGpPWpGaD
Darifenacin—CHRM2—Signaling by GPCR—CCL5—acquired immunodeficiency syndrome	1.22e-05	0.00107	CbGpPWpGaD
Darifenacin—CHRM1—Signaling by GPCR—CSF2—acquired immunodeficiency syndrome	1.22e-05	0.00107	CbGpPWpGaD
Darifenacin—CHRM3—Signaling by GPCR—CSF2—acquired immunodeficiency syndrome	1.21e-05	0.00107	CbGpPWpGaD
Darifenacin—CHRM2—GPCR downstream signaling—CCR5—acquired immunodeficiency syndrome	1.21e-05	0.00106	CbGpPWpGaD
Darifenacin—CHRM2—Signaling by GPCR—CSF2—acquired immunodeficiency syndrome	1.2e-05	0.00106	CbGpPWpGaD
Darifenacin—CHRM1—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	1.13e-05	0.000993	CbGpPWpGaD
Darifenacin—CHRM3—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	1.12e-05	0.000989	CbGpPWpGaD
Darifenacin—CHRM2—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	1.11e-05	0.00098	CbGpPWpGaD
Darifenacin—CHRM1—Signaling by GPCR—CCR5—acquired immunodeficiency syndrome	1.11e-05	0.000979	CbGpPWpGaD
Darifenacin—CHRM3—Signaling by GPCR—CCR5—acquired immunodeficiency syndrome	1.11e-05	0.000976	CbGpPWpGaD
Darifenacin—CHRM2—Signaling by GPCR—CCR5—acquired immunodeficiency syndrome	1.1e-05	0.000967	CbGpPWpGaD
Darifenacin—CHRM4—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	1.08e-05	0.000952	CbGpPWpGaD
Darifenacin—CHRM4—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	1.07e-05	0.000938	CbGpPWpGaD
Darifenacin—CYP3A4—Metabolism—AGPS—acquired immunodeficiency syndrome	1.06e-05	0.000937	CbGpPWpGaD
Darifenacin—CHRM4—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	1.05e-05	0.000924	CbGpPWpGaD
Darifenacin—CHRM5—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	1.04e-05	0.000912	CbGpPWpGaD
Darifenacin—CHRM5—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	1.02e-05	0.000898	CbGpPWpGaD
Darifenacin—CHRM1—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	1.02e-05	0.000898	CbGpPWpGaD
Darifenacin—CHRM3—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	1.02e-05	0.000895	CbGpPWpGaD
Darifenacin—CHRM2—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	1.01e-05	0.000886	CbGpPWpGaD
Darifenacin—CHRM5—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	1.01e-05	0.000885	CbGpPWpGaD
Darifenacin—CHRM4—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	9.75e-06	0.000858	CbGpPWpGaD
Darifenacin—CHRM1—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	9.6e-06	0.000844	CbGpPWpGaD
Darifenacin—CHRM1—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	9.6e-06	0.000844	CbGpPWpGaD
Darifenacin—CHRM3—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	9.57e-06	0.000841	CbGpPWpGaD
Darifenacin—CHRM3—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	9.57e-06	0.000841	CbGpPWpGaD
Darifenacin—CHRM4—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	9.54e-06	0.000839	CbGpPWpGaD
Darifenacin—CHRM2—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	9.47e-06	0.000833	CbGpPWpGaD
Darifenacin—CHRM2—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	9.47e-06	0.000833	CbGpPWpGaD
Darifenacin—CHRM5—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	9.34e-06	0.000821	CbGpPWpGaD
Darifenacin—CHRM5—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	9.14e-06	0.000803	CbGpPWpGaD
Darifenacin—CHRM1—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	7.3e-06	0.000642	CbGpPWpGaD
Darifenacin—CHRM3—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	7.28e-06	0.00064	CbGpPWpGaD
Darifenacin—CHRM2—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	7.21e-06	0.000634	CbGpPWpGaD
Darifenacin—CHRM1—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	7.19e-06	0.000632	CbGpPWpGaD
Darifenacin—CHRM3—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	7.17e-06	0.00063	CbGpPWpGaD
Darifenacin—CHRM2—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	7.1e-06	0.000624	CbGpPWpGaD
Darifenacin—CHRM1—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	7.08e-06	0.000623	CbGpPWpGaD
Darifenacin—CHRM3—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	7.06e-06	0.000621	CbGpPWpGaD
Darifenacin—CHRM2—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	6.99e-06	0.000615	CbGpPWpGaD
Darifenacin—CHRM1—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	6.58e-06	0.000578	CbGpPWpGaD
Darifenacin—CHRM3—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	6.56e-06	0.000577	CbGpPWpGaD
Darifenacin—CHRM2—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	6.49e-06	0.000571	CbGpPWpGaD
Darifenacin—CHRM1—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	6.43e-06	0.000566	CbGpPWpGaD
Darifenacin—CHRM3—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	6.41e-06	0.000564	CbGpPWpGaD
Darifenacin—CHRM2—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	6.35e-06	0.000558	CbGpPWpGaD
Darifenacin—CHRM4—Signaling Pathways—IL2—acquired immunodeficiency syndrome	5.64e-06	0.000496	CbGpPWpGaD
Darifenacin—CHRM4—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	5.61e-06	0.000493	CbGpPWpGaD
Darifenacin—CHRM3—Metabolism—ALB—acquired immunodeficiency syndrome	5.59e-06	0.000491	CbGpPWpGaD
Darifenacin—CHRM5—Signaling Pathways—IL2—acquired immunodeficiency syndrome	5.4e-06	0.000475	CbGpPWpGaD
Darifenacin—CHRM5—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	5.37e-06	0.000472	CbGpPWpGaD
Darifenacin—CHRM1—Signaling Pathways—IL2—acquired immunodeficiency syndrome	3.8e-06	0.000334	CbGpPWpGaD
Darifenacin—CHRM3—Signaling Pathways—IL2—acquired immunodeficiency syndrome	3.79e-06	0.000333	CbGpPWpGaD
Darifenacin—CHRM1—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	3.78e-06	0.000333	CbGpPWpGaD
Darifenacin—CHRM3—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	3.77e-06	0.000331	CbGpPWpGaD
Darifenacin—CHRM2—Signaling Pathways—IL2—acquired immunodeficiency syndrome	3.75e-06	0.00033	CbGpPWpGaD
Darifenacin—CHRM2—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	3.73e-06	0.000328	CbGpPWpGaD
Darifenacin—CYP2D6—Metabolism—ALB—acquired immunodeficiency syndrome	3.34e-06	0.000294	CbGpPWpGaD
Darifenacin—CHRM4—Signaling Pathways—IL6—acquired immunodeficiency syndrome	3.31e-06	0.000291	CbGpPWpGaD
Darifenacin—CHRM5—Signaling Pathways—IL6—acquired immunodeficiency syndrome	3.17e-06	0.000279	CbGpPWpGaD
Darifenacin—CHRM1—Signaling Pathways—IL6—acquired immunodeficiency syndrome	2.23e-06	0.000196	CbGpPWpGaD
Darifenacin—CHRM3—Signaling Pathways—IL6—acquired immunodeficiency syndrome	2.23e-06	0.000196	CbGpPWpGaD
Darifenacin—CHRM2—Signaling Pathways—IL6—acquired immunodeficiency syndrome	2.2e-06	0.000194	CbGpPWpGaD
Darifenacin—CYP3A4—Metabolism—ALB—acquired immunodeficiency syndrome	2.18e-06	0.000192	CbGpPWpGaD
